Mac-1 expression and binding of either anti-MPO or anti-OVA by circulating neutrophils in wild-type mice pretreated with LPS (0.1 μg, 4 hours)
| Population . | Proportion of total neutrophils . | M1/70 MFI . | % +ve for anti-OVA or anti-MPO . | Anti-MPO MFI . |
|---|---|---|---|---|
| LPS + anti-OVA, n = 6 | ||||
| Gr-1hi/M1/70int | All | 72 ± 12 | 1% ± 1% (anti-OVA+ve) | — |
| LPS + anti-MPO, n = 6 | ||||
| Gr-1hi/M1/70hi | 70% ± 14% | 449 ± 74 | 91% ± 6% (anti-MPO+ve) | 81 ± 33 |
| Gr-1lo/M/1/70hi+ | 30% ± 14% | 1252 ± 414 | 70% ± 17% (anti-MPO+ve) | 90 ± 39 |
| Population . | Proportion of total neutrophils . | M1/70 MFI . | % +ve for anti-OVA or anti-MPO . | Anti-MPO MFI . |
|---|---|---|---|---|
| LPS + anti-OVA, n = 6 | ||||
| Gr-1hi/M1/70int | All | 72 ± 12 | 1% ± 1% (anti-OVA+ve) | — |
| LPS + anti-MPO, n = 6 | ||||
| Gr-1hi/M1/70hi | 70% ± 14% | 449 ± 74 | 91% ± 6% (anti-MPO+ve) | 81 ± 33 |
| Gr-1lo/M/1/70hi+ | 30% ± 14% | 1252 ± 414 | 70% ± 17% (anti-MPO+ve) | 90 ± 39 |
Data are shown as mean ± SEM.
— indicates not applicable.